deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 11-arm NCT04152499

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (MK-2870-001)

A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

Sponsor: Klus Pharma Inc.

Conditions Breast Cancer Cervical Cancer Endometrial Carcinoma Epithelial Ovarian Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Head and Neck Squamous Cell Carcinoma Non-Small Cell Lung Cancer Small-Cell Lung Cancer Urothelial Carcinoma
Interventions SKB264
Updated 17 times since 2019 Last updated: May 15, 2025 Started: Feb 28, 2020 Primary completion: Dec 31, 2025 Completion: Jul 16, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer and Cervical Cancer, this trial is ongoing. The trial is conducted by Klus Pharma Inc. and has accumulated 17 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Dec 2022 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Mar 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  12. Dec 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Klus Pharma Inc.
Data source: Klus Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anyang, China , Beijing, China , Bengbu, China , Binzhou, China , Busan, South Korea , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Daegu, South Korea and 53 more locations